Find a Trial

Trial Results


15 protocol(s) meet the specified criteria
CTO-208887OPEN TO ACCRUAL
A Phase I/II Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM5
CTO-64007957MMY1004OPEN TO ACCRUAL
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma
CTO-CAEL101-301OPEN TO ACCRUAL
CTO-CAEL101-302OPEN TO ACCRUAL
CTO-FT576-101OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
CTO-MT-0169-001OPEN TO ACCRUAL
A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients With Relapsed or Refractory Multiple Myeloma
CTO-R5458-ONC-1826OPEN TO ACCRUAL
A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
CTO-TAK-981-1503OPEN TO ACCRUAL
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUCRO-0373OPEN TO ACCRUAL
A Path Analysis Modeling of the Interaction of AXII and/or AXIIR with the Changes in Cytokines and Myeloma Bone Disease (The Cytokine Protocol)
IUCRO-0381OPEN TO ACCRUAL
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease: An Exploratory Model
IUCRO-0498OPEN TO ACCRUAL
Role of Osteocytes in Myeloma Bone Disease
IUSCC-0633OPEN TO ACCRUAL
Prospective Observation of the Incidence and Natural History of Monoclonal Gammopathy in Patients Undergoing Weight Reduction Surgery
IUSCC-0661OPEN TO ACCRUAL
The Indiana Myeloma Registry
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer